Neutrophil/Lymphocyte Ratio
Inflammatory marker and immune health indicator
3 providers include this
Additional Specialized Tests
Normal:<3.0, Elevated:>3.0
What is Neutrophil/Lymphocyte Ratio?
Inflammatory marker and immune health indicator
Why It Matters
Elevated ratio indicates systemic inflammation and stress. Predicts cardiovascular events and mortality. Simple marker of immune activation.
Which Providers Test Neutrophil/Lymphocyte Ratio?
Full Provider Comparison
| Provider | Includes | Annual Cost | Biomarkers |
|---|---|---|---|
 Superpower | ✓ | $199 | 100+ (150 with ratios) |
 WHOOP Advanced Labs | — | $349 | 65 |
 Labcorp OnDemand | — | $398 | 30+ |
| — | $486 | 40+ | |
| — | $444 | 288 | |
| — | $349 | 100+ | |
| — | $761 | 54 | |
 Function Health | ✓ | $365 | 160+ |
| — | $250 | 65 | |
| — | $495 | 70+ | |
| — | $895 | 100+ | |
| — | $1950 | 150+ | |
| — | $375 | 80+ | |
| — | $Varies | 75+ | |
| — | $190 | 100+ | |
| — | $99 | 50 | |
| — | $124 | 60 | |
| — | $199 | 50 | |
| — | $499 | 120+ | |
| ✓ | $4188 | 70-80+ | |
| — | $375 | 85 | |
| — | $700 | 128 |
Frequently Asked Questions
What is Neutrophil/Lymphocyte Ratio?
Inflammatory marker and immune health indicator
What is the optimal range for Neutrophil/Lymphocyte Ratio?
The standard reference range for Neutrophil/Lymphocyte Ratio is Normal:<3.0, Elevated:>3.0. Optimal ranges may differ based on individual health goals and expert recommendations.
Which blood test providers include Neutrophil/Lymphocyte Ratio?
3 out of 22 blood testing providers include Neutrophil/Lymphocyte Ratio in their panels. This biomarker has limited availability.
What category does Neutrophil/Lymphocyte Ratio fall under?
Neutrophil/Lymphocyte Ratio is categorized under Additional Specialized Tests. This category includes biomarkers that help assess related aspects of health and wellness.
Medical Disclaimer
This information is for educational purposes only and is not medical advice. Always consult with a qualified healthcare provider about your specific health needs.
Last reviewed:2026-02-20